On January 23, 2024 Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, reported invite to a conference call on the updated data from the ongoing phase 1b/2a study in advanced hepatocellular carcinoma (HCC) (Press release, Medivir, JAN 23, 2024, View Source [SID1234639440]). The data was presented at the ASCO (Free ASCO Whitepaper) (American Society of Clinical Oncology) GI (Gastrointestinal Cancers) Symposium in San Francisco on January 19. The conference call will be held today January 23, at 14.00 CET, to update on the results in the study and the plans moving forward, including feedback from extensive interactions with world renowned experts at the ASCO (Free ASCO Whitepaper) GI congress.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The data (poster number 476P) from the ongoing fostrox + Lenvima study, presented on Friday January 19 by Dr Maria Reig from Hospital Clinic of Barcelona in Spain, showed that fostrox + Lenvima remains tolerable, with no new, unexpected safety events and that the clinical benefit continues to improve further, as the study progresses and data matures.
– "The updated study results presented at ASCO (Free ASCO Whitepaper) GI has further strengthened our belief in the combination of fostrox + Lenvima as a potential treatment for patients with advanced HCC. The conference also enabled extensive interactions with global experts in HCC which provided important input regarding the design of our upcoming study. Expert guidance is of particular value when preparing for interactions with regulatory authorities to discuss final study design of the planned, registrational phase 2b study with accelerated approval intent," says Dr. Pia Baumann, CMO at Medivir.
Conference call for investors, analysts and the media
Presenters from Medivir: Jens Lindberg, CEO, Pia Baumann, CMO and Fredrik Öberg, CSO.
Time: Tuesday January 23, 2024, at 14.00 CET
To access the webcast and information about the teleconference, please click HERE!
The webcast will also be streamed via a link on the website: www.medivir.com/investors/calendar
The presentation will be available on Medivir’s website after the conference call.
The poster will also be available on Medivir’s website.
For additional information, please contact;
Magnus Christensen, CFO, Medivir AB
Telephone: +46 8 5468 3100
E-mail: [email protected]
About fostrox
Fostrox is a type of smart chemotherapy that delivers the cell-killing compound selectively to the tumor while minimizing the harmful effect on normal cells. This is achieved by coupling an active chemotherapy (troxacitabine) with a prodrug tail. The prodrug design enables fostrox to be administered orally and travel directly to the liver where the active substance is released locally in the liver. With this unique mechanism, fostrox has the potential to become the first liver-targeted, orally administered drug that can help patients with various types of liver cancer. A phase 1b monotherapy study with fostrox has been completed and a phase 1b/2a combination study in HCC is ongoing.
About primary liver cancer
Primary liver cancer is the third leading cause of cancer-related deaths worldwide and hepatocellular carcinoma (HCC) is the most common cancer that arises in the liver. Although existing therapies for advanced HCC can extend the lives of patients, treatment benefits are insufficient and death rates remain high. There are approximately 660,000 patients diagnosed with primary liver cancer per year globally and current five-year survival is less than 20 percent2. HCC is a heterogeneous disease with diverse etiologies, and lacks defining mutations observed in many other cancers. This has contributed to the lack of success of molecularly targeted agents in HCC. The limited overall benefit, taken together with the poor overall prognosis for patients with intermediate and advanced HCC, results in a large unmet medical need.